EGFR and colorectal carcinoma: A preclinical study using IL-21 combined with cetuximab (an anti-EGFR monoclonal antibody) indicated an activation of immune response biomarkers on NK and T cells in stage IV CRC patients, yet it did not evaluate treatment efficacy (160).